.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
UBS
Express Scripts
US Army
Julphar
McKesson
Harvard Business School
Deloitte
Moodys
Accenture

Generated: September 19, 2017

DrugPatentWatch Database Preview

Sandoz Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?

SANDOZ INC has one hundred and forty-four approved drugs.

There are two US patents protecting SANDOZ INC drugs. There are fifteen tentative approvals on SANDOZ INC drugs.

There are twenty patent family members on SANDOZ INC drugs in eighteen countries.

Summary for Applicant: Sandoz Inc

Patents:2
Tradenames:117
Ingredients:112
NDAs:144
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
ROCURONIUM BROMIDE
rocuronium bromide
INJECTABLE;INJECTION079195-001Dec 5, 2008APRXNoYes► Subscribe► Subscribe► Subscribe
Sandoz Inc
GUANFACINE HYDROCHLORIDE
guanfacine hydrochloride
TABLET, EXTENDED RELEASE;ORAL202568-002Jun 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
ENALAPRIL MALEATE
enalapril maleate
TABLET;ORAL075621-003Aug 22, 2000DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
CARBOPLATIN
carboplatin
INJECTABLE;IV (INFUSION)078280-001May 8, 2008APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER
clindamycin phosphate
INJECTABLE;INJECTION201692-002May 31, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
DOXYCYCLINE
doxycycline
TABLET;ORAL065353-002Nov 27, 2006DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
BUSULFAN
busulfan
INJECTABLE;INJECTION205106-001Jul 7, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
HALOPERIDOL DECANOATE
haloperidol decanoate
INJECTABLE;INJECTION076463-002Jun 24, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
OFLOXACIN
ofloxacin
SOLUTION/DROPS;OTIC078222-001Mar 17, 2008ATRXNoNo► Subscribe► Subscribe► Subscribe
Sandoz Inc
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
polymyxin b sulfate; trimethoprim sulfate
SOLUTION/DROPS;OPHTHALMIC064211-001Apr 13, 1998ATRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Sandoz Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,261,547 Gelling ophthalmic compositions containing xanthan gum► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sandoz Inc Drugs

Country Document Number Estimated Expiration
Brazil9910113► Subscribe
New Zealand506921► Subscribe
Austria245451► Subscribe
Turkey200002848► Subscribe
Canada2322579► Subscribe
Australia3194799► Subscribe
Canada2505836► Subscribe
China1133466► Subscribe
Australia740586► Subscribe
Hong Kong1031335► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sandoz Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0090France► SubscribePRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
C/GB02/031United Kingdom► SubscribePRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
2009Austria► SubscribePRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
C0118France► SubscribePRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107
/2000Austria► SubscribePRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
C/GB98/017United Kingdom► SubscribePRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
C0019France► SubscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
2013025,C1304992Lithuania► SubscribePRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
0136011/03Switzerland► SubscribePRODUCT NMAE: ESTRADIOL UND MEDROXYPROGESTERONACETAT; REGISTRATION NO/DATE: IKS 55288 20000417
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Novartis
Express Scripts
AstraZeneca
Fish and Richardson
Cerilliant
Teva
UBS
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot